Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest MetaStat Inc. Stories

2012-11-26 08:23:28

MONTCLAIR, N.J., Nov. 26, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST) today announced the October 31, 2012 online publication of "Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients" in Breast Cancer Research, an international, peer-reviewed online journal. Dr. John S. Condeelis, Chairman of MetaStat's Scientific Advisory Board, is senior on the publication. Dr. Condeelis holds The...

2012-11-14 08:31:28

MONTCLAIR, N.J., Nov. 14, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST), a life science company focused on the development and commercialization of proprietary clinical diagnostics that predict the probability of systemic hematogenous (blood borne) metastasis, as well as companion therapeutics to prevent this deadly spread, today announced that its common stock has been approved for quotation on the OTC Bulletin Board ("OTCBB") commencing with the start of...

2012-05-02 06:25:44

THE WOODLANDS, Texas, May 2, 2012 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST) ("MetaStat" or the "Company") announced today that on May 1, 2012, it has received subscriptions in a private placement for aggregate gross proceeds of $805,000 from certain accredited and institutional investors (the "Offering"). The Offering consisted of the issuance by the Company of 805,000 shares of the Company's common stock at $1.00 per share and 201,250 common stock purchase warrants with an exercise...

2012-04-27 06:23:34

THE WOODLANDS, Texas, April 27, 2012 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST) announced today that it has executed two additional license agreements to patent applications and technology from the Albert Einstein College of Medicine of Yeshiva University. The first license agreement covers U.S. Patent Application No. 12/998,237 entitled "An In Vivo Quantitative Screening Test for Anti-Metastasis Treatment Efficacy"; inventors: Jeffrey Edward Segall, John S. Condeelis, Dmitriy Kedrin, Jacco...

2012-04-20 02:22:32

NEW YORK, April 20, 2012 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), formerly (OTCBB: PVSO), ("MetaStat" or the "Company"), a life science company focused on developing and commercializing proprietary clinical diagnostic tests that predict the probability of cancer metastasis, as well as companion therapeutics to prevent systemic metastasis, today announced that it has changed its name from PhotoVoltaic Solar Cells, Inc. to MetaStat, Inc. effective April 9, 2012. In connection with this...

2012-02-28 07:30:00

NEW YORK, Feb. 28, 2012 /PRNewswire/ -- PhotoVoltaic Solar Cells, Inc. (OTCBB: PVSO) ("PhotoVoltaic" or the "Company") announced today, that effective February 27, 2012, it completed a share exchange with MetaStat, Inc. (MetaStat"), a life science company focused on developing and commercializing proprietary clinical diagnostic tests that predict the probability of cancer metastasis, as well as companion therapeutics to prevent systemic metastasis. In connection with the...

2012-02-28 07:30:00

NEW YORK, Feb. 28, 2012 /PRNewswire/ -- PhotoVoltaic Solar Cells, Inc. (OTCBB: PVSO) ("PhotoVoltaic" or the "Company") announced today, that effective February 27, 2012, it completed a share exchange with MetaStat, Inc. (MetaStat"), a life science company focused on developing and commercializing proprietary clinical diagnostic tests that predict the probability of cancer metastasis, as well as companion therapeutics to prevent systemic metastasis. In connection with the transaction,...